Novel targeted therapeutics can help to combat tumor resistance to anti-cancer treatment resulting in recurrence development. Carcinoma cell membranes represent a large potential source of druggable therapeutic targets. Proteomics is a promising tool for developing potential therapeutic targets. Proteome-based evaluation of membrane fractions helps to detect potential therapeutic targets.